Inhibition of tissue factor by ixolaris reduces primary tumor growth and experimental metastasis in a murine model of melanoma

Thrombosis Research

Volumn 130, Issue 3, 2012, Pages

  De Oliveira, Andreia Da Silva ^a   Lima, Luize G ^a   Mariano Oliveira, Andréa ^a   MacHado, Daniel E ^a   Nasciutti, Luiz E ^a   Andersen, John F ^b   Petersen, Lars C ^c   Francischetti, Ivo M B ^b   Monteiro, Robson Q ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NOVO NORDISK A S   (Denmark)

Author keywords

angiogenesis; anticoagulant therapy; ixolaris; melanoma; metastasis; Tissue factor

Indexed keywords

ANTINEOPLASTIC AGENT; IXOLARIS; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; LUNG NODULE; LUNG TUMOR; MELANOMA; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL ENLARGEMENT; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MELANOMA; MICE; MICE, INBRED C57BL; SALIVARY PROTEINS AND PEPTIDES; THROMBOPLASTIN; TREATMENT OUTCOME;

EID: 84865219979     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.05.021     Document Type: Article

References (55)

1. F.R. Rickles, and A. Falanga Molecular basis for the relationship between thrombosis and cancer Thromb Res 102 2001 V215 V224
2. R. Sud, and A.A. Khorana Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model Thromb Res 123 Suppl. 4 2009 S18 S21
3. M. Davila, A. Amirkhosravi, E. Coll, H. Desai, L. Robles, and J. Colon Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation J Thromb Haemost 6 2008 1517 1524
4. L.G. Lima, A.S. Oliveira, L.C. Campos, M. Bonamino, R. Chammas, and C. Werneck Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles Thromb Haemost 106 2011 712 723
5. A.K. Kakkar, N.R. Lemoine, M.F. Scully, S. Tebbutt, and R.C. Williamson Tissue factor expression correlates with histological grade in human pancreatic cancer Br J Surg 82 1995 1101 1104
6. J. Rak, C. Milsom, L. May, P. Klement, and J. Yu Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy Semin Thromb Hemost 32 2006 54 70
7. F.S. Ribeiro, T.A. Simao, N.D. Amoedo, N.A. Andreollo, L.R. Lopes, and R. Acatauassu Evidence for increased expression of tissue factor and protease-activated receptor-1 in human esophageal cancer Oncol Rep 21 2009 1599 1604
8. N. Nitori, Y. Ino, Y. Nakanishi, T. Yamada, K. Honda, and K. Yanagihara Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma Clin Cancer Res 11 2005 2531 2539
9. G. Patry, H. Hovington, H. Larue, F. Harel, Y. Fradet, and L. Lacombe Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer Int J Cancer 122 2008 1592 1597
10. E.O. Maciel, G.F. Carvalhal, V.D. da Silva, E.L. Batista Jr., and B. Garicochea Increased tissue factor expression and poor nephroblastoma prognosis J Urol 182 2009 1594 1599
11. B.M. Mueller, R.A. Reisfeld, T.S. Edgington, and W. Ruf Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis Proc Natl Acad Sci U S A 89 1992 11832 11836
12. J.S. Palumbo, and J.L. Degen Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis Thromb Res 120 Suppl. 2 2007 S22 S28
13. M. Sawada, S. Miyake, S. Ohdama, O. Matsubara, S. Masuda, and K. Yakumaru Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis Br J Cancer 79 1999 472 477
14. T. Nakasaki, H. Wada, C. Shigemori, C. Miki, E.C. Gabazza, and T. Nobori Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer Am J Hematol 69 2002 247 254
15. R.T. Poon, C.P. Lau, J.W. Ho, W.C. Yu, S.T. Fan, and J. Wong Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma Clin Cancer Res 9 2003 5339 5345
16. A.A. Khorana, S.A. Ahrendt, C.K. Ryan, C.W. Francis, R.H. Hruban, and Y.C. Hu Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer Clin Cancer Res 13 2007 2870 2875
17. Y. Zhang, Y. Deng, T. Luther, M. Muller, R. Ziegler, and R. Waldherr Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice J Clin Invest 94 1994 1320 1327
18. W. Ruf, J. Disse, T.C. Carneiro-Lobo, N. Yokota, and F. Schaffner Tissue factor and cell signalling in cancer progression and thrombosis J Thromb Haemost 9 2011 306 315
19. H.H. Versteeg, F. Schaffner, M. Kerver, H.H. Petersen, J. Ahamed, and B. Felding-Habermann Inhibition of tissue factor signaling suppresses tumor growth Blood 111 2008 190 199
20. S.N. Markovic, L.A. Erickson, R.D. Rao, R.H. Weenig, B.A. Pockaj, and A. Bardia Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis Mayo Clin Proc 82 2007 364 380
21. S.N. Markovic, L.A. Erickson, R.D. Rao, R.H. Weenig, B.A. Pockaj, and A. Bardia Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment Mayo Clin Proc 82 2007 490 513
22. D.L. Ornstein, and L.R. Zacharski Treatment of cancer with anticoagulants: rationale in the treatment of melanoma Int J Hematol 73 2001 157 161
23. M. Amarzguioui, Q. Peng, M.T. Wiiger, V. Vasovic, E. Babaie, and T. Holen Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells Clin Cancer Res 12 2006 4055 4061
24. T.M. Niers, L.W. Bruggemann, C.P. Klerk, F.J. Muller, T. Buckle, and P.H. Reitsma Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung Clin Exp Metastasis 26 2009 171 178
25. I.M. Francischetti, J.G. Valenzuela, J.F. Andersen, T.N. Mather, and J.M. Ribeiro Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex Blood 99 2002 3602 3612
26. R.Q. Monteiro, A.R. Rezaie, J.M. Ribeiro, and I.M. Francischetti Ixolaris: a factor Xa heparin-binding exosite inhibitor Biochem J 387 2005 871 877
27. R.Q. Monteiro, A.R. Rezaie, J.S. Bae, E. Calvo, J.F. Andersen, and I.M. Francischetti Ixolaris binding to factor X reveals a precursor state of factor Xa heparin-binding exosite Protein Sci 17 2008 146 153
28. R.A. Nazareth, L.S. Tomaz, S. Ortiz-Costa, G.C. Atella, J.M. Ribeiro, and I.M. Francischetti Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade Thromb Haemost 96 2006 7 13
29. J.F. Andersen, X.D. Ding, C. Balfour, T.K. Shokhireva, D.E. Champagne, and F.A. Walker Kinetics and equilibria in ligand binding by nitrophorins 1-4: evidence for stabilization of a nitric oxide-ferriheme complex through a ligand-induced conformational trap Biochemistry 39 2000 10118 10131
30. L.C. Petersen, P.L. Norby, S. Branner, B.B. Sorensen, T. Elm, and H.R. Stennicke Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study Thromb Res 116 2005 75 85
31. R.S. Fernandes, C. Kirszberg, V.M. Rumjanek, and R.Q. Monteiro On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells J Thromb Haemost 4 2006 1546 1552
32. D.E. Machado, M.S. Abrao, P.T. Berardo, C.M. Takiya, and L.E. Nasciutti Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum Fertil Steril 90 2008 148 155
33. T. Knudsen, O.H. Olsen, and L.C. Petersen Tissue factor and factor VIIa cross-species compatibility Front Biosci 17 2011 3196 3215
34. J. Zhao, G. Aguilar, S. Palencia, E. Newton, and A. Abo rNAPc2 inhibits colorectal cancer in mice through tissue factor Clin Cancer Res 15 2009 208 216
35. T.C. Carneiro-Lobo, S. Konig, D.E. Machado, L.E. Nasciutti, M.F. Forni, and I.M. Francischetti Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model J Thromb Haemost 7 2009 1855 1864
36. D.M. Mizurini, I.M.B. Francischetti, J.F. Andersen, and R.Q. Monteiro Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasis Thromb Haemost 104 2010 1116 1123
37. H. Isawa, M. Yuda, K. Yoneda, and Y. Chinzei The insect salivary protein, prolixin-S, inhibits factor IXa generation and Xase complex formation in the blood coagulation pathway J Biol Chem 275 2000 6636 6641
38. C. Kirszberg, L.G. Lima, de O.A. Da Silva, W. Pickering, E. Gray, and T.W. Barrowcliffe Simultaneous tissue factor expression and phosphatidylserine exposure account for the highly procoagulant pattern of melanoma cell lines Melanoma Res 19 2009 301 308
39. N. Esumi, D. Fan, and I.J. Fidler Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor Cancer Res 51 1991 4549 4556
40. T.A. Hembrough, G.M. Swartz, A. Papathanassiu, G.P. Vlasuk, W.E. Rote, and S.J. Green Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism Cancer Res 63 2003 2997 3000
41. K.M. Donnelly, M.E. Bromberg, A. Milstone, J.M. Madison McNiff, G. Terwilliger, and W.H. Konigsberg Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro Thromb Haemost 79 1998 1041 1047
42. J.S. Palumbo, K.W. Kombrinck, A.F. Drew, T.S. Grimes, J.H. Kiser, and J.L. Degen Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells Blood 96 2000 3302 3309
43. F. Langer, A. Amirkhosravi, S.B. Ingersoll, J.M. Walker, B. Spath, and B. Eifrig Experimental metastasis and primary tumor growth in mice with hemophilia A J Thromb Haemost 4 2006 1056 1062
44. J.S. Palumbo, K.A. Barney, E.A. Blevins, M.A. Shaw, A. Mishra, and M.J. Flick Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function J Thromb Haemost 6 2008 812 819
45. M.L. Nierodzik, K. Chen, K. Takeshita, J.J. Li, Y.Q. Huang, and X.S. Feng Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis Blood 92 1998 3694 3700
46. M.E. Bromberg, M.A. Bailly, and W.H. Konigsberg Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor Thromb Haemost 86 2001 1210 1214
47. C. Kirszberg, V.M. Rumjanek, and R.Q. Monteiro Assembly and regulation of prothrombinase complex on B16F10 melanoma cells Thromb Res 115 2005 123 129
48. Y.J. Yin, Z. Salah, M. Maoz, S.C. Ram, S. Ochayon, and G. Neufeld Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation FASEB J 17 2003 163 174
49. G.J. Villares, M. Zigler, H. Wang, V.O. Melnikova, H. Wu, and R. Friedman Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA Cancer Res 68 2008 9078 9086
50. E. Yang, A. Boire, A. Agarwal, N. Nguyen, K. O'Callaghan, and P. Tu Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis Cancer Res 69 2009 6223 6231
51. L. Hu, M. Lee, W. Campbell, R. Perez-Soler, and S. Karpatkin Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis Blood 104 2004 2746 2751
52. H.H. Versteeg, F. Schaffner, M. Kerver, L.G. Ellies, P. Andrade-Gordon, and B.M. Mueller Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice Cancer Res 68 2008 7219 7227
53. A. Dutra-Oliveira, R.Q. Monteiro, and A. Mariano-Oliveira Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines Biochem Biophys Res Commun 421 2012 221 227
54. I. Depasquale, and W.D. Thompson Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF Histopathology 52 2008 500 509
55. E. Cocco, J. Varughese, N. Buza, S. Bellone, M. Glasgow, and M. Bellone Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor BMC Cancer 11 2011 263